Ann Pediatr Endocrinol Metab.  2017 Dec;22(4):240-246. 10.6065/apem.2017.22.4.240.

Development of disease-specific growth charts in Turner syndrome and Noonan syndrome

• Isojima T
• Yokoya S

• KMID: 2400780
• DOI: http://doi.org/10.6065/apem.2017.22.4.240

Abstract

Many congenital diseases are associated with growth failure, and patients with these diseases have specific growth patterns. As the growth patterns of affected individuals differ from those of normal populations, it is challenging to detect additional conditions that can influence growth using standard growth charts. Disease-specific growth charts are thus very useful tools and can be helpful for understanding the growth pattern and pathogenesis of congenital diseases. In addition, disease-specific growth charts allow doctors to detect deviations from the usual growth patterns for early diagnosis of an additional condition and can be used to evaluate the effects of growth-promoting treatment for patients. When developing these charts, factors that can affect the reliability of the charts should be considered. These factors include the definition of the disease with growth failure, selection bias in the measurements used to develop the charts, secular trends of the subjects, the numbers of subjects of varying ages and ethnicities, and the statistical method used to develop the charts. In this review, we summarize the development of disease-specific growth charts for Japanese individuals with Turner syndrome and Noonan syndrome and evaluate the efforts to collect unbiased measurements of subjects with these diseases. These charts were the only available disease-specific growth charts of Turner syndrome and Noonan syndrome for Asian populations and were developed using a Japanese population. Therefore, when these charts are adopted for Asian populations other than Japanese, different growth patterns should be considered.

Keyword

Growth charts; Disease-specific growth chart; Turner syndrome; Noonan syndrome; LMS method; Asian population

MeSH Terms

Asian Continental Ancestry Group
Early Diagnosis
Growth Charts*
Humans
Methods
Noonan Syndrome*
Selection Bias
Turner Syndrome*

Figure

• 

  Fig. 1. Growth charts for the normal Japanese population [46] superimposed on the normal Korean population [47].

Reference

References

1. Hermanussen M. Auxology: an update. Horm Res Paediatr. 2010; 74:153–64.

2. de Onis M, Wijnhoven TM, Onyango AW. Worldwide practices in child growth monitoring. J Pediatr. 2004; 144:461–5.

3. Ranke MB. Disease-specific standards in congenital syndromes. Horm Res. 1996; 45 Suppl 2:35–41.

4. Nagai T, Matsuo N, Kayanuma Y, Tonoki H, Fukushima Y, Ohashi H, et al. Standard growth curves for Japanese patients with Prader-Willi syndrome. Am J Med Genet. 2000; 95:130–4.

5. Styles ME, Cole TJ, Dennis J, Preece MA. New cross sectional stature, weight, and head circumference references for Down's syndrome in the UK and Republic of Ireland. Arch Dis Child. 2002; 87:104–8.

6. Martin ND, Smith WR, Cole TJ, Preece MA. New height, weight and head circumference charts for British children with Williams syndrome. Arch Dis Child. 2007; 92:598–601.

7. Isojima T, Yokoya S, Ito J, Horikawa R, Tanaka T. New reference growth charts for Japanese girls with Turner syndrome. Pediatr Int. 2009; 51:709–14.

8. Isojima T, Yokoya S, Ito J, Naiki Y, Horikawa R, Tanaka T. Proposal of new auxological standards for Japanese girls with turner syndrome. Clin Pediatr Endocrinol. 2010; 19:69–82.

9. Isojima T, Sakazume S, Hasegawa T, Ogata T, Nakanishi T, Nagai T, et al. Growth references for Japanese individuals with Noonan syndrome. Pediatr Res. 2016; 79:543–8.

10. Isojima T, Sakazume S, Hasegawa T, Ogata T, Nakanishi T, Nagai T, et al. Validation of auxological reference values for Japanese children with Noonan syndrome and comparison with growth in children with Turner syndrome. Clin Pediatr Endocrinol. 2017; 26:153–64.

11. Saenger P. Turner's syndrome. N Engl J Med. 1996; 335:1749–54.

12. Ranke MB, Saenger P. Turner's syndrome. Lancet. 2001; 358:309–14.

13. Sybert VP, McCauley E. Turner's syndrome. N Engl J Med. 2004; 351:1227–38.

14. Ranke MB, Grauer ML. Adult height in Turner syndrome: results of a multinational survey 1993. Horm Res. 1994; 42:90–4.

15. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985; 60:932–5.

16. Rongen-Westerlaken C, Corel L, van den Broeck J, Massa G, Karlberg J, Albertsson-Wikland K, et al. Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH treatment. Acta Paediatr. 1997; 86:937–42.

17. Haeusler G, Schemper M, Frisch H, Blümel P, Schmitt K, Plöchl E. Spontaneous growth in Turner syndrome: evidence for a minor pubertal growth spurt. Eur J Pediatr. 1992; 151:283–7.

18. Bertapelli F, Barros-Filho Ade A, Antonio MÂ, Barbeta CJ, de Lemos-Marini SH, Guerra-Junior G. Growth curves for girls with Turner syndrome. Biomed Res Int. 2014; 2014:687978.

19. Darendeliler F, Yeşilkaya E, Bereket A, Baş F, Bundak R, Sarı E, et al. Growth curves for Turkish Girls with Turner Syndrome: Results of the Turkish Turner Syndrome Study Group. J Clin Res Pediatr Endocrinol. 2015; 7:183–91.

20. Suwa S. Standards for growth and growth velocity in Turner's syndrome. Acta Paediatr Jpn. 1992; 34:206–20.

21. Naeraa RW, Nielsen J. Standards for growth and final height in Turner's syndrome. Acta Paediatr Scand. 1990; 79:182–90.

22. Massa G, Vanderschueren-Lodeweyckx M, Malvaux P. Linear growth in patients with Turner syndrome: influence of spontaneous puberty and parental height. Eur J Pediatr. 1990; 149:246–50.

23. Ranke MB, Pflüger H, Rosendahl W, Stubbe P, Enders H, Bierich JR, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr. 1983; 141:81–8.

24. Tanaka T, Takano K, Hanew K, Nishi Y, Igarashi Y, Hirano T, et al. Registration system for growth hormone (GH) treatment with standardized immunoreactive GH values in Japan. Endocr J. 1998; 45:459–65.

25. Isojima T, Yokoya S, Ito J, Horikawa R, Tanaka T. Trends in age and anthropometric data at start of growth hormone treatment for girls with Turner syndrome in Japan. Endocr J. 2008; 55:1065–70.

26. Mochizuki T, Fujita K, Yokoya S. A questionnaire survey of the follow-up status in adult Turner women in Japan. Jpn J Pediatr. 2010; 114:43–7.

27. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010; 126:746–59.

28. Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA. The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child. 1974; 127:48–55.

29. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet. 1985; 21:493–506.

30. Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. 1968; 116:373–80.

31. Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD. Noonan syndrome: the changing phenotype. Am J Med Genet. 1985; 21:507–14.

32. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001; 29:465–8.

33. Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet. 2013; 93:173–80.

34. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci. 2010; 1214:99–121.

35. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010; 1:2–26.

36. van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007; 2:4.

37. van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E. Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet. 1994; 53:187–91.

38. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR. Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr. 1988; 148:220–7.

39. Witt DR, Keena BA, Hall JG, Allanson JE. Growth curves for height in Noonan syndrome. Clin Genet. 1986; 30:150–3.

40. Malaquias AC, Brasil AS, Pereira AC, Arnhold IJ, Mendonca BB, Bertola DR, et al. Growth standards of patients with Noonan and Noonan-like syndromes with mutations in the RAS/MAPK pathway. Am J Med Genet A. 2012; 158A:2700–6.

41. Otten BJ, Noordam C. Growth in Noonan syndrome. Horm Res. 2009; 72 Suppl 2:31–5.

42. Noonan JA, Raaijmakers R, Hall BD. Adult height in Noonan syndrome. Am J Med Genet A. 2003; 123A:68–71.

43. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992; 11:1305–19.

44. Wright EM, Royston P. A comparison of statistical methods for age-related reference intervals. J Royal Stat Soc A. 1997; 160:47–69.

45. Cole TJ. Fitting smoothed centile curves to reference data. J Royal Stat Soc A. 1988; 151:385–418.

46. Isojima T, Kato N, Ito Y, Kanzaki S, Murata M. Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey. Clin Pediatr Endocrinol. 2016; 25:71–6.

47. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008; 51:1–25.